A&O Shearman Steers GSK's $2.2B Rapt Therapeutics Deal
GSK PLC said Tuesday it has agreed to acquire U.S.-based Rapt Therapeutics Inc. in a deal valued at $2.2 billion, in a bid to strengthen the British drugmaker's portfolio of respiratory,...To view the full article, register now.
Already a subscriber? Click here to view full article